(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-carbamic acid methyl ester | 383430-77-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-carbamic acid methyl ester
• 英文别名: methyl N-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]carbamate
• CAS: 383430-77-1
• 化学式: C₂₅H₂₁N₅O₃
• 分子量: 439.473
• InChiKey: PBAROTCYIIEPJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  98.3
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Small molecules for the treatment of abnormal cell growth
  申请人：Pfizer Inc.

  公开号：US20030171386A1

  公开（公告）日：2003-09-11

  This invention relates to small molecules that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such small molecules in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds. The invention further relates to small molecules that are selective for erbB2 receptor over the erbB1 receptor, wherein said erbB2 inhibitor has a range of selectivities for erbB2 over erbB1 between 50-1500.

  本发明涉及小分子化合物，可用于治疗哺乳动物中的异常细胞生长，如癌症。本发明还涉及使用这些小分子化合物治疗哺乳动物中的异常细胞生长的方法，特别是人类，并涉及含有这些化合物的制药组合物。本发明进一步涉及选择性针对erbB2受体而非erbB1受体的小分子化合物，其中所述erbB2抑制剂对erbB2与erbB1的选择性范围在50-1500之间。
• SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Pfizer Products Inc.

  公开号：EP1292591B1

  公开（公告）日：2005-02-02
• QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Pfizer Products Inc.

  公开号：EP1465632A1

  公开（公告）日：2004-10-13
• [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH<br/>[FR] DERIVES DE QUINAZOLINE POUR LE TRAITEMENT DE CROISSANCE CELLULAIRE ANORMALE
  申请人：PFIZER PROD INC

  公开号：WO2003049740A1

  公开（公告）日：2003-06-19

  This invention relates to quinazoline derivatives that are usefulin the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such small molecules in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds. The invention further relates to small molecules that are selective for erbB2 receptor over the erbB1 receptor, wherein said erbB2 inhibitor has a range of selectivities for erbB2 over erbB1 between 50-1500.